GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Cash from Discontinued Operating Activities

MBCOF (Marvel Biosciences) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Marvel Biosciences's Cash from Discontinued Operating Activities for the three months ended in Jan. 2025 was $0.00 Mil. It means Marvel Biosciences received $0.00 Mil from discontinued investing activities. Marvel Biosciences's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Jan. 2025 was $0.00 Mil.

Marvel Biosciences Cash from Discontinued Operating Activities Historical Data

The historical data trend for Marvel Biosciences's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Cash from Discontinued Operating Activities Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Cash from Discontinued Operating Activities
- - - - -

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Marvel Biosciences Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Cash from Discontinued Operating Activities
Comparable Companies
XCNQ:MYND XCNQ:NURL XCNQ:LOBE TSXV:XRTX XCNQ:AGN XCNQ:RIZE XCNQ:MOOD XCNQ:ASEP XCNQ:HEAL TSX:APLI VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.